Table 3.
Top 10 product classes in African reports vs. RoW reports
| ATC code | Africa (%)a | RoW (%)b |
|---|---|---|
| J05AF—nucleoside and nucleotide reverse transcriptase inhibitors | 14,530 (14.04) | 44,055 (0.38) |
| J05AG—non-nucleoside reverse transcriptase inhibitors | 9407 (9.09) | 26,107 (0.22) |
| J05AR—antivirals for the treatment of HIV infections, combinations | 5692 (5.50) | 34,927 (0.30) |
| J01EE—combinations of sulfonamides and trimethoprim, incl. derivatives | 3082 (2.98) | 81,206 (0.69) |
| C09AA—ACE inhibitors, plain | 2503 (2.42) | 154,176 (1.32) |
| S01AA—antibiotics | 2340 (2.26) | 179,635 (1.53) |
| J07AH—meningococcal vaccines | 2308 (2.23) | 48,480 (0.41) |
| L03AB—interferons | 2130 (2.06) | 211,098 (1.80) |
| J04AM—combinations of drugs for treatment of tuberculosis | 1933 (1.87) | 7043 (0.06) |
| D06AX—other antibiotics for topical use | 1855 (1.79) | 103,228 (0.88) |
RoW rest of the world, ATC anatomic therapeutic chemical, ACE angiotensin-converting enzyme, ICSRs individual case safety reports
aPercentage includes all African ICSRs (n = 103,499) in VigiBase® (excluding Swaziland, n = 27)
bPercentage of all RoW ICSRs (n = 11,721,305) in VigiBase®